EDNRA and pulmonary arterial hypertension: PAH is characterized by increased levels of the vasoconstrictor endothelin-1, and, therefore, along with increasing nitric oxide, the antagonism of the endothelin-1 receptor is effective PAH therapy that may be beneficial in COVID-19 infection [102].